pramipexole has been researched along with oxybutynin in 8 studies
| Studies (pramipexole) | Trials (pramipexole) | Recent Studies (post-2010) (pramipexole) | Studies (oxybutynin) | Trials (oxybutynin) | Recent Studies (post-2010) (oxybutynin) |
|---|---|---|---|---|---|
| 1,103 | 219 | 517 | 2,607 | 619 | 1,670 |
| Protein | Taxonomy | pramipexole (IC50) | oxybutynin (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.5951 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.027 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.002 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0032 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0035 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.0027 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.5951 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.6 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.4288 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.792 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.0855 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.0242 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bachmann, CG; Berg, D; Berkels, R; Grieger, F; Hofmann, WE; Lauterbach, T; Schollmayer, E; Stiasny-Kolster, K | 1 |
| Mackie, SE; Mei, LA; Platt, S; Schoerning, L; Winkelman, JW | 1 |
| Ma, Y; Sui, D; Wang, L; Wang, Y; Xu, H; Yu, X; Zhang, P | 1 |
| Frampton, JE | 1 |
| Antonini, A; Durner, G; Falup-Pecurariu, C; Henriksen, T; Kessel, B; Martinez-Martin, P; Odin, P; Ray Chaudhuri, K; Rizos, A; Sauerbier, A; Silverdale, M | 1 |
| Kalia, YN; Merino, V; Serna, C; Singhal, M | 1 |
2 review(s) available for pramipexole and oxybutynin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Rotigotine Transdermal Patch: A Review in Parkinson's Disease.
Topics: Administration, Cutaneous; Dopamine Agonists; Humans; Indoles; Parkinson Disease; Pramipexole; Quality of Life; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2019 |
1 trial(s) available for pramipexole and oxybutynin
| Article | Year |
|---|---|
Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany.
Topics: Aged; Benzothiazoles; Dopamine Agonists; Female; Germany; Humans; Levodopa; Male; Middle Aged; Pramipexole; Restless Legs Syndrome; Self Administration; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2013 |
5 other study(ies) available for pramipexole and oxybutynin
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.
Topics: Administration, Oral; Aged; Benzothiazoles; Dopamine Agonists; Drug Synergism; Female; Humans; Indoles; Male; Pramipexole; Restless Legs Syndrome; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes; Time Factors; Transdermal Patch | 2016 |
Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Cutaneous; Animals; Apoptosis; Corpus Striatum; Delayed-Action Preparations; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Male; Mice, Inbred C57BL; Mitochondria; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Pramipexole; Superoxide Dismutase; Transdermal Patch | 2018 |
Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson's disease patients: an European multicentre survey.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Dopamine Agonists; Humans; Middle Aged; Parkinson Disease; Pramipexole; Retrospective Studies; Tetrahydronaphthalenes; Transdermal Patch | 2020 |
Current profile controlled transdermal delivery of pramipexole from an iontophoretic patch system in vitro and in vivo.
Topics: Animals; Delayed-Action Preparations; Dopamine Agonists; Drug Delivery Systems; Electrochemical Techniques; Iontophoresis; Pramipexole; Rats; Swine; Transdermal Patch; Treatment Outcome | 2021 |